TAKARA HOLDINGS INC.

NEWS RELEASE

This page introduces the press release provided to journalists.

2005

page top

2005.12.15

Takara Bio Inc. to supply RetroNectin® to City of Hope's HIV/AIDS gene therapy study

2005.12.13

MolMed S.p.A., Takara Bio's strategic partner in gene therapy, presents
positive results of its Phase I/II clinical trial of HSV-TK gene therapy in
high risk leukemia

2005.09.01

Notice of Completion of Acquisition of Clontech Operations

2005.07.29

Notice of Increase in Capital of Subsidiary

2005.07.01

Takara Bio to Acquire ClontechUnit of BD Biosciences

2005.01.24

Patents obtained in Japan and the United States for biomarkers useful in
treatment of refractory leukemia

2005.01.13

Takara Bio Inc. announced that its partner MolMed S.p.A. plans to enter
into Phase III clinical studies on HSV-TK gene therapy project this year

page top